RECOXA 15mg. 20 tablets
Recoxa is a medicinal product with a strong anti-inflammatory effect, relieves pain and reduces increased body temperature. Belongs to the so-called non-steroidal anti-inflammatory drugs (NSAIDs).
Recoxa is intended for the symptomatic treatment of rheumatic diseases, e. osteoarthritis, rheumatoid arthritis, ankylosing spondylitis (ankylosing spondylitis). Medicinal product is intended for adults and adolescents over 15 years.
2. BEFORE YOU USE RECOXA
Do not use Recoxa
Recoxa should not be used in patients with known hypersensitivity to meloxicam or any of the excipients. Recoxa should not be used by patients who are aspirin or other NSAIDs induce asthmatic problems, nasal polyps, angioedema / edema caused by allergy) or hives.
The medicinal product must not be used by patients with active or recurrent (recurrent) ulcer or bleeding in the stomach or duodenum, bleeding or perforation of the gastrointestinal tract in the past related to past treatment with NSAIDs with severe hepatic impairment, severe renal failure who are not on dialysis (can not be subjected to dialysis), bleeding in the brain or other disorders related to bleeding, or severe heart failure.
Recoxa should not be used by children and adolescents under 15 years of age.
Recoxa should not be used during the third trimester of pregnancy.
• Special care is needed:
Drugs such as Recoxa may be associated with a small increased risk of heart attack ("myocardial infarction") or stroke. Any risk is more likely with high doses and prolonged treatment. Do not exceed the recommended dose and duration of treatment.
If you have heart problems, previous stroke or think that you might be at risk of these conditions (for example if you have high blood pressure, diabetes, high cholesterol or are a smoker) you should discuss your treatment with your doctor or pharmacist.
Concomitant use of Recoxa with other NSAIDs should be avoided.
Similarly, as with other medicinal products of the class of NSAIDs during treatment may occur in the digestive tract bleeding, ulceration or perforation, accompanied or not by warning signs or transient symptoms. These disorders are usually more severe in the elderly.
The occurrence of bleeding or ulceration of the gastrointestinal tract in patients receiving Recoxa, treatment should be discontinued.
Recoxa should be used with caution in patients with gastrointestinal disease in the past (ulcerative colitis, Crohn's disease) as their condition may deteriorate.
NSAIDs can cause deterioration of renal function in patients with low blood volume and decreased renal blood flow. Usually (after discontinuation of these products) depressed renal function recovered completely to the values before treatment. In this case, high risk patients are those who are dehydrated (dehydrated), heart failure, liver cirrhosis, kidney disease, patients treated with diuretics or those with major surgery. These patients should be carefully monitored during initiation of treatment.
Patients suffering from kidney disease, those treated with diuretics and patients blood volume is reduced and blood flow through the kidneys is limited for various reasons, can use Recoxa only if especially important reasons.
Caution is recommended in patients with a history of hypertension (high blood pressure) and / or heart failure, as have been observed in fluid retention and edema related to treatment with Recoxa.
Taking Recoxa should be discontinued at the first appearance of skin rash, lesions (damage) of the mucous membranes or any other sign of hypersensitivity.
As with other NSAIDs, it is sometimes observed change the parameters of liver function. In the majority of cases they are small and transient. If the change is significant or long continued, the application of Recoxa should be discontinued and should be monitored values of abnormal liver function tests.
There is no need for dose adjustment in patients with clinically stable liver cirrhosis. However, patients with cirrhosis of the liver can use Recoxa only if there are serious reasons for that use.
Weak patients and those with a weaker constitution can show a poor tolerance to potential side effects and they should be monitored carefully.
Recoxa may mask signs of concurrent infectious disease.
In the case of unsatisfactory therapeutic effect, the recommended daily dosage should not be exceeded. If the patient's condition does not improve within a few days, the benefit of treatment should be reassessed.
Using other medicines
Please tell your doctor or pharmacist if you are using or have recently used any other medicines, including those sold without a prescription.
When concomitant administration of Recoxa and medicinal products that reduce blood clots, heparin injection and substances dissolving blood clots may increase the risk of bleeding. If you are using a combination of medicines, blood coagulation should be monitored frequently.
If you are using methotrexate simultaneously Recoxa, you need to have regular blood tests. Not recommended concomitant Recoxa in patients treated with high doses of methotrexate (more than 15 mg / week /
Recoxa medicinal product may reduce the contraceptive efficacy of intrauterine systems.
At the same time Recoxa use drugs stimulating urine output should eat enough fluids and to conduct regular tests of kidney function.
Concomitant use of medicinal products Recoxa and lowering high blood pressure reduces the effectiveness of these products.
Coadministration of Recoxa and ACE inhibitors or angiotensin II receptor antagonists in the elderly and / or dehydrated patients may lead to acute renal failure. It is therefore advisable to monitor renal function at the initiation of treatment and ensuring adequate intake of fluids from the patient.
The concomitant use of cholestyramine and Recoxa leads to enhanced release of meloxicam (cholestyramine binds meloxicam in the gastrointestinal tract), reducing its effectiveness.
If you are using cyclosporin with Recoxa during treatment should conduct regular tests of kidney function.
There may be an increased risk of seizures when Recoxa be administered concurrently with quinolones.
Taking Recoxa with food and drink
Absorption is not affected by concomitant administration of food. The tablets should be taken during meals with water or other liquid.
Pregnancy and lactation
Consult your doctor or pharmacist before taking any medicine.
Recoxa should not be used during the third trimester of pregnancy. If it is necessary Recoxa should not be used during the first and second trimester of pregnancy and during lactation.
Recoxa use can damage a woman's ability to become pregnant and is not recommended for women who are trying to conceive. In women who are trying to conceive or carry out research for sterility should be considered discontinuation of meloxicam.
Driving and using machines
The medicinal product does not affect attention and ability to concentrate. In case of occurrence of side effects such as abnormal vision, dizziness or drowsiness, the product may adversely affect the activities requiring alertness, coordination of movements and rapid decision-making (eg. While driving, operating machinery or heights) . The occurrence of these side effects, you should not perform tasks requiring alertness.
Important information about some of the ingredients
Recoxa contains lactose. If your doctor has warned that you have an intolerance to some sugars, talk to him before you start using Recoxa.
3. HOW TO TAKE RECOXA?
Always being treated in accordance with the instructions of your doctor. If you are unsure should consult your doctor or pharmacist.
Rheumatoid arthritis usually patients should take one tablet Rekoksa15 mg daily, but if necessary, the dose can be reduced to half a tablet Recoxa 15 mg (7,5 mg meloxicam) per day.
Osteoarthritis patients usually take half a tablet Recoxa 15 mg (7,5 mg meloxicam) per day, but if necessary, the dose may be increased to one tablet Recoxa 15 mg daily.
Ankylosing spondylitis: a tablet Recoxa 15 mg daily.
In patients in whom the risk of side effects is increased, treatment is usually started at a dose of half a tablet Recoxa 15 mg (7,5 mg meloxicam) per day.
In patients with renal failure who are on dialysis, the dose should not exceed half a tablet Recoxa 15 (7,5 mg meloxicam) per day. Meloxicam is contraindicated in patients with severe renal failure who are not on dialysis (can not be subjected to dialysis) or severely impaired liver function.
The maximum recommended daily dose of medicinal product Recoxa 15 mg dose is one tablet (15 mg meloxicam).
The overall daily dose should be administered as a single dose once daily.
If you take more tablets Recoxa than you should:
If you shi someone else has taken more tablets Recoxa than necessary, seek immediate medical attention.
The symptoms of an overdose are: lethargy, drowsiness, nausea, vomiting, epigastric pain (podzhlachnata area), including blurred vision, gastrointestinal perforations (small holes in the gastrointestinal tract), inflammation of the stomach, inflammatory bowel disease, inflammatory liver, renal insufficiency, Stevens Johnson syndrome and toxic epidermal necrolysis (acute disease of the skin), angioedema (swelling, occurring as a result of an allergic reaction), erythema multiforme (red spots on the skin of different shapes), hypersensitivity of the skin to light.
Drugs such as Recoxa may be associated with a small increased risk of heart attack ("myocardial infarction") or stroke.
In case of bleeding from the digestive tract, seek medical advice immediately and discontinue use of this product.
In case of adverse reactions of the mucous membranes or skin, discontinue use of this product and seek medical advice.
If any of the side effects are severe or if you notice any not listed in this leaflet, please inform your doctor or pharmacist.
5. HOW TO STORE RECOXA?
Keep out of the reach of children.
Recoxa not use after the expiry date stated on the packaging. The expiry date refers to the last day of that month.
Do not store above 25 ° C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicine that you do not need more. These measures will help to protect the environment.
6. FURTHER INFORMATION
Active substance: Meloxicam 15 mg per tablet.
Excipients: lactose monohydrate, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate, sodium citrate dihydrate, crospovidone.
Appearance and contents of container
Recoxa 15: light yellow, round, biconvex tablets with bevelled and engraved on one side, the same of which is scored and smooth reverse side. 10 tablets are packed in blister. One or more blister packed in a cardboard box.
Contents of the package: Recoxa 15: 10, 20, 30, 60 or 100 tablets